Activation of circulating platelets in vaccine-induced thrombotic thrombocytopenia and its reversal by intravenous immunoglobulin

Vaccine-induced thrombotic thrombocytopenia (VITT) is a serious side-effect of the ChAdOx1 nCoV-19 vaccine (Oxford/AstraZeneca BioPharmaceuticals, Cambridge, UK) occurring in approximately one in 26 000 to one in 100 000 vaccine recipients. More recently similar thrombotic complications have been reported for the Ad26.COV2.S coronavirus disease 2019 (COVID-19) vaccine (Janssen/Johnson & Johnson, New Brunswick, NJ, USA). Vaccine-induced thrombotic thrombocytopenia can result in life-threatening thrombotic complications involving different vascular beds, including the pulmonary, cerebral and splanchic circulations in conjunction with thrombocytopenia and markedly raised D-dimer. Although the precise mechanisms underpinning the development of VITT are unknown, the resemblance to the pathology seen in patients with heparin-induced thrombocytopenia (HIT), has guided our understanding, research efforts and therapy of VITT. It is currently proposed that VITT is caused by pathological immunoglobulin G (IgG) antibodies directed against platelet factor 4 (PF4, potentially complexed with components of the ChAdOx1 nCoV-19 vaccine), which can induce platelet activation via cross-linked platelet Fc gamma receptor IIa (FcγRIIa) receptors. Based on this proposed mechanism, intravenous Ig (IVIg) therapy is recommended as a cornerstone in the treatment of VITT.

Recently published reports suggested that components of serum/plasma from patients with VITT can activate platelets isolated from healthy donors. However, to date, no direct evidence of platelet activation in patients with VITT has been reported. In the present study, we report the presence of activated circulating platelets in a patient with VITT, using whole blood flow cytometry, and confirm that IVIg treatment reduces platelet activation in VITT.

Case report

We report a 55-year-old female with a background history of hypertrophic cardiomyopathy, ischaemic heart disease, obstructive sleep apnoea, epilepsy, and schizophrenia, who presented to hospital with chest pain 14 days after the first dose of the ChAdOx1 nCoV-19 vaccine. Consistent with a diagnosis of VITT, her platelet count was 45 × 10^9/l with a D-dimer of 65-94 mg/ml and strongly positive HIT enzyme-linked immunosorbent assay (ELISA, 143-9%; normal cut-off 10-5% – Stago Asserachrom, Diagnostica Stago S.A.S., Asnières-sur-Seine, France) (Fig 1). A subsequent computed tomography (CT) pulmonary angiogram demonstrated bilateral pulmonary emboli and venous doppler ultrasonography revealed a proximal deep vein thrombosis involving the popliteal vein. Therapeutic anticoagulation was commenced with fondaparinux 7.5 mg subcutaneously daily and IVIg was administered at a dose of 90 g (1 g/kg). Informed consent was obtained, and blood samples were taken before and after the administration of IVIg for flow cytometry analysis of platelet activation. Over the following 5 days the platelet count steadily incremented, which was associated with a concordant fall in the D-dimer. However, 6 days after the initial dose of IVIg the patient developed chest pain and dyspnoea, in association with a reduction in platelet count to 108 × 10^9/l. Subsequent imaging with a CT pulmonary angiogram revealed a reduction in thrombus burden of the left lung; however, demonstrated extension of thrombosis within the segmental and subsegmental vessels of the right lower lobe. Therefore, fondaparinux was changed to bivalirudin and a further dose of IVIg (1 g/kg) was administered. This was associated with an increment of the platelet count to 157 × 10^9/l.

Over the following days, the platelet count remained normal and the patient at the time of reporting is stably anticoagulated with bivalirudin and being transitioned to oral anticoagulation with a vitamin K antagonist, given the known interactions of carbamazepine with direct oral anticoagulants.

Results

Prior to IVIg administration a significant percentage of platelets were positive for markers of platelet activation. Indeed, 13% of platelets expressed activated glycoprotein IIb/IIIa (GPIIb/IIIa, CD41/CD61, αIIbβ3) with 19-1% demonstrating P-selectin [CD62P, granule membrane protein-140 (GMP-140)] surface expression (Fig 2). In keeping with the significant degree of platelet activation there was a significant increase in platelet–monocyte aggregates, with 26-5% of monocytes displaying evidence of bound platelets. Strikingly, repeat testing after IVIg administration demonstrated that levels of PAC-1 binding, P-selectin expression, and platelet–monocyte aggregates had returned to a level comparable to a healthy donor. These data suggest that a significant percentage of circulating platelets in patients with VITT are highly activated. The finding of elevated levels of circulating...
platelet–monocyte aggregates is indicative of platelet activation; however, also suggests that monocyte activation is a feature of VITT. Overall, these findings are consistent with the pro-thrombotic presentation of our patient with VITT.

**Discussion**

To our knowledge, the present case provides the first direct evidence of a patient with VITT presenting with activated platelets in the circulation and the first direct evidence of the ability of IVIg to abrogate this enhanced platelet activation state in VITT. Recent reports have suggested that plasma/serum of patients with VITT have the propensity to activate platelets from healthy donors. Our present report is the first to show that a large number of activated platelets are present in the circulating blood of a patient with VITT. The flow cytometric data demonstrating platelet activation is very robust: (i) Binding of PAC-1 identifies platelets with the activated GPIIb/IIIa receptor. The conformational change of this integrin from a low- to a high-affinity state for its ligand is reflecting the final common pathway of platelet activation. (ii) P-selectin expression on the platelet surface represents platelet degranulation, as P-selectin is 'stored' in α-granules, which are fused with the membrane upon platelet stimulation. (iii) Platelet–monocyte aggregate formation is a sensitive marker of platelet activation and has previously been found to be elevated in various thrombotic disorders such as acute coronary syndromes. Moreover, GPIIb/IIIa activation and P-selectin expression have previously been used to demonstrate platelet activation associated with HIT and GPIIb/IIIa inhibitor-induced thrombocytopenia. The reported data are also unique in respect to the high percentage of platelets circulating in an activated state, further highlighting the acuteness and severity of VITT.

The finding of increased numbers of platelet–monocyte aggregates is important as they are not only a sensitive marker of platelet activation but are also likely reflective of enhanced monocyte activation as a feature of VITT. Activated monocytes have been implicated in the pathogenesis of HIT, given they express the FcγRIIa receptor and therefore are also liable to activation by pathogenic antibodies. Whilst platelet–monocyte aggregates have previously been associated with venous thromboembolic disease, HIT, and severe COVID-19 infection, the number of platelet–monocyte aggregates detected, and the finding that this number is reduced after IVIg administration is a novel and important finding. This also strongly suggests that these changes are the result of pathological VITT antibodies. Similar trends were seen in our present patient with platelet–neutrophil aggregates, which is of particular relevance as neutrophil extracellular trap formation has been proposed to be involved in VITT. Although not elucidated in the present report, previous reports from both patients with VITT and HIT suggest the beneficial effects of IVIg in modulating platelet activation are likely due to the ability to competitively inhibit pathological antibody binding to platelet FcγRIIa receptors.
Notably, the clinical course of our present patient experiencing thrombus extension 6 days after IVIg likely suggests that high levels of Ig are required to competitively inhibit platelet FcγRIIa receptor binding. This raises the interesting possibility of whether changes in platelet activation markers can be utilised to assess the response to IVIg treatment and/or potentially help predict treatment relapse. Collectively, these findings support the role of platelet activation as a central mechanism of VITT and confirm the beneficial role of IVIg in preventing platelet activation.

### Acknowledgements

James D. McFadyen designed research, analysed data and wrote the paper. Prerna Sharma performed research and analysed data. Mitchell J. Moon performed research and analysed data. Jonathon Noonan analysed data. Elizabeth Goodall analysed data. Huyen A. Tran analysed data and wrote the paper. Karlheinz Peter designed research, analysed data and wrote the paper.

### Funding information

The study was funded by the National Health and Medical Research Council of Australia.

James D. McFadyen1,2,3,4
Prerna Sharma1
Mitchell J. Moon1,4
Jonathan Noonan1,4
Elizabeth Goodall2
Huyen A. Tran2,3
Karlheinz Peter1,3,4,5

1Atherothrombosis and Vascular Biology, Baker Heart and Diabetes Institute, 2Department of Clinical Hematology, The Alfred Hospital, 3Department of Medicine, Central Clinical School, Monash University,
Advances in the treatment of follicular lymphoma (FL) have fostered the hope that some patients may be cured with the use of immunochemotherapy. In patients who are destined for long-term survival and possible cure, attention is turning toward reducing toxicity and improving quality of life. The relative differences in morbidity and mortality attributable to induction regimen-related adverse events (AEs), now assume much greater significance. Current up-front chemoinmunotherapy combinations are accompanied by AEs in up to 97% and serious AEs in up to 50% of FL patients treated first-line. The single-centre phase II INITIAL (ANZCTR 1260700153415) study using iodine-131-rituximab (131I-RIT) delivered in an outpatient setting without chemotherapy, demonstrated a complete metabolic remission (CR) in 82% of patients at three months and a median time-to-next-treatment (TTNT) not reached (median follow-up of 4.25 years). Compared with chemoimmunotherapy combinations, a single episode of treatment with 131I-RIT resulted in no significant serious or fatal adverse event during induction/maintenance. The relative absence of toxicity of 131I-RIT supported the previously demonstrated safety and efficacy of...